


## ML2006a4

<b>Cat. No.:</b>	HY-158073
<b>CAS No.:</b>	2943213-62-3
<b>Molecular Formula:</b>	C <sub>30</sub> H <sub>44</sub> F <sub>3</sub> N <sub>5</sub> O <sub>6</sub>
<b>Molecular Weight:</b>	627.7
<b>Target:</b>	SARS-CoV
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	ML2006a4 is an orally active inhibitor for SARS-CoV-2 main protease (M <sup>Pr</sup> ) with IC <sub>50</sub> in picomolare value. ML2006a4 is cell permeable and antiviral active, that inhibits replication in SARS-CoV-2 in cells Huh7.5.1-ACE2-TMPRSS2 (Huh7.5.1++) in picomolare level <sup>[1]</sup>
<b>In Vitro</b>	ML2006a4 (0-10 μM) reveals an antiviral activity in cells Huh7.5.1++ and A549-ACE2 (A549+), with EC <sub>50</sub> s of 100 and 120 nM, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	ML2006a4 (20 mg/kg, i.v.) reveals a pharmacokinetic profiles with an oral bioavailability of 27% (40 mg/kg, p.o.) and a plasma clearance rate C <sub>pl</sub> of 39 mL/min/kg and Volume of distribution at steady state V <sub>ss</sub> 0.66 L/kg <sup>[1]</sup> . ML2006a4 (40 mg/kg, p.o., twice a day for 4 days) ameliorates the SARS-CoV-2 infection, exhibits viral inhibitory and lung protective efficacy in BALB/c mice without significant toxicity <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>Animal Model:</b>	SARS-CoV-2 MA10 infected BALB/c mice <sup>[1]</sup>
<b>Dosage:</b>	40 mg/kg
<b>Administration:</b>	p.o., twice a day for 4 days
<b>Result:</b>	Reduced inflammation and respiratory epithelial injury, improved epithelial regeneration and the survival rates with minimal weight loss.

### REFERENCES

[1]. Westberg M, et al., An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Sci Transl Med. 2024 Mar 13;16(738):eadi0979.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA